Injectable amniotic membrane/umbilical cord particulate for facet joint syndrome: A retrospective, single-center study

2021 ◽  
pp. 1-6
Author(s):  
Ramon Castellanos
Keyword(s):  
Umbilical Cord ◽  
Amniotic Membrane ◽  
Facet Joint ◽  
High Rate ◽  
Single Center ◽  
Opioid Prescription ◽  
Patient Global Impression ◽  
Single Center Study ◽  
Percent Improvement ◽  
Global Impression Of Change

BACKGROUND: Facet joint syndrome (FJS) pain is a significant contributor to back pain and has a high rate of opioid prescription. Unfortunately, there are a limited number of therapeutic options for these patients. OBJECTIVE: To evaluate the safety and effectiveness of amniotic membrane/umbilical cord particulate (AM/UC) in managing FJS pain. METHODS: A single-center, investigator-initiated, retrospective study was performed on consecutive patients with FJS pain who received intra- or peri-articular injection of AM/UC between July 1, 2018 and July 26, 2019. Primary outcome was change in Patient Global Impression of Change (PGIC) at 6 weeks, 3 months, 6 months, and 12 months to assess the self-reported percent improvement relative to baseline. Safety was assessed by AM/UC- and procedure-related complications. Paired t-tests were used to determine whether there is a statistically significant improvement of pain post-injection compared to baseline. RESULTS: There were a total of 54 patients (69.7 ± 13.4 years; 31 female) presenting baseline pain score of 9.2 ± 1.0 despite prior treatments of activity modification (66.7%), NSAIDs (61.1%), opioids (37.0%), and physical therapy (35.2%). Mean GPIC improvement was 65.3%, 67.5%, 56.9%, and 56.7% among responders30, respectively. There were no complications. CONCLUSION: This study supports the safety and effectiveness of AM/UC particulate injection in managing FJS pain.

scholarly journals Electrical stimulation therapy of the lower esophageal sphincter in GERD patients—a prospective single-center study

2020 ◽  
Author(s):  
Matthias Paireder ◽  
Ivan Kristo ◽  
Milena Nikolic ◽  
Gerd Jomrich ◽  
Johannes Steindl ◽  
...  
Keyword(s):  
Electrical Stimulation ◽  
Side Effects ◽  
Lower Esophageal Sphincter ◽  
High Rate ◽  
Single Center ◽  
Electrical Stimulation Therapy ◽  
Novel Technique ◽  
Single Center Study ◽  
Esophageal Sphincter ◽  
Center Study

Summary Background Electrical stimulation therapy (EST) of the lower esophageal sphincter (LES) for gastro esophageal reflux disease (GERD) treatment increases LES pressure through chronic stimulation, with a low risk for gastrointestinal side effects and preservation of hiatal anatomy. The aim of this study was to evaluate the efficacy and safety of this novel technique in a high-output specialized reflux center. Methods This is a prospective single-center study including GERD patients indicated for anti-reflux therapy who consented to undergo LES-EST. Patients underwent prospective scheduled follow-up visits including interrogation of the stimulation device, clinical examination, and assessment of health-related quality of life (HRQL). Results Within a 4-year period, 37 LES-EST implantations were performed. The majority of patients were male (54.1%), mean BMI was 25.8 (SD 4.4), and mean age was 54.0 (SD 15.8). The median GERD HRQL composite score was 41 (IQR 21–49). Median total % of pH <4 was 10.1 (IQR 4.4–17.3). Six (16.2%) individuals underwent explantation of the entire system (IPG and leads) due to technical defect (n = 4) or failure of therapy (n = 2). HRQL score improved from 41 (IQR 21–49) to 8.50 (IQR 4.25–20.5, p < 0.001) and 9 (23.7%) patients were on at least occasional PPI treatment. Conclusion Due to the low rate of GI side effects and its minimal invasive character preserving the hiatal anatomy, this novel technique might find its place in anti-reflux surgery. However, the considerably high rate of device dysfunction needs further investigation.

Comparison of Outcomes of Unrelated Bone Marrow and Umbilical Cord Blood Transplants in Children with Hematologic Malignancies: Single Center Study in Korea.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5164-5164
Author(s):  
Nak-Gyun Chung ◽  
Bin Cho ◽  
Young-Shil Park ◽  
Dae-Chul Jeong ◽  
Pil-Sang Jang ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Hematologic Malignancies ◽  
Bone Marrow Transplants ◽  
Single Center ◽  
Hematopoietic Stem ◽  
Single Center Study ◽  
Center Study

Abstract In order to compare the outcomes of unrelated umbilical cord blood transplants (UCBT) or bone marrow transplants, 102 children with hematologic malignancies transplanted with unrelated umbilical cord blood (n=35, M:F=21:14, median age 4 years) or unrelated bone marrow transplants (UBMT) (n= 67, M:F=49:18, median age 9 years) were analyzed in a retrospective single center study (between Aug. 1997 and Dec. 2003 in the Catholic Hematopoietic Stem Cell Transplantation Center of Korea). HLA mismatches were defined by serology for class I and molecular typing for DRB1. The donor was HLA mismatched in 94% of UCBTs (33 of 35 UCBT) and in 0 % of UBMT. Non-adjusted estimates of 2-year event-free survival rates were 46 % and 57 %, respectively (P > 0.2). Engraftment failures of donor cells occurred in 17 % (6 out of 35) of UCBT and in 6 % (4 out of 67) of UBMT. Grade >= III acute GVHDs developed in 3 out of 29 (10 %) engrafted patients who underwent UCBT and in 17 out of 63 (27 %) engrafted patients who underwent UBMT. Early TRM at day 100 was 31 % (11 out of 35) for UCBT and 22 % (12 out of 67) for UBMTs. Within post-transplant month 3, CMV infections occurred in 37 % of UCBT and 54 % of UBMT, but most of them did not progress to CMV disease due to early ganciclovir treatment. Chronic GVHD developed in 2 out of 22 (9 %) patients who underwent UCBT and in 15 out of 49 (31 %) patients underwent UBMT. In conclusion, the use of UCBT as a source of hematopoietic stem cells is a reasonable option for children with hematologic malignancies lacking an acceptable, matched unrelated marrow donor.

scholarly journals Injectable Amniotic Membrane/Umbilical Cord Particulate for Knee Osteoarthritis: A Prospective, Single-Center Pilot Study

Pain Medicine ◽  
2019 ◽  
Vol 20 (11) ◽  
pp. 2283-2291 ◽  
Author(s):  
Ramon Castellanos ◽  
Sean Tighe
Keyword(s):  
Pilot Study ◽  
Knee Osteoarthritis ◽  
Physical Function ◽  
Umbilical Cord ◽  
Amniotic Membrane ◽  
Single Center ◽  
Medication Usage ◽  
Knee Oa ◽  
Symptomatic Knee ◽  
Magnetic Resonance Imaging Mri

Abstract Objective To evaluate the short-term safety and effectiveness of amniotic membrane/umbilical cord particulate (AMUC) in managing pain in patients with various severities of knee osteoarthritis (OA). Design Single-center, prospective, investigator-initiated pilot study. Setting Private practice. Subjects A total of 20 knee OA patients aged ≥18 years were enrolled with pain >40 mm, as determined by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)–A. Methods Patients received an ultrasound-guided, intra-articular injection of 50 mg of AMUC particulate reconstituted in 2 mL of preservative-free saline. All patients were then monitored at six weeks, 12 weeks, and 24 weeks postinjection. Patients who did not show >30% reduction in pain received a second injection of AMUC at six weeks. WOMAC, Patient Global Assessment, medication usage, and magnetic resonance imaging (MRI) were assessed. Results Knee OA pain significantly decreased from 74.3 ± 17.2 at baseline to 45.0 ± 25.4 at six weeks (P < 0.01), 35.4 ± 26.6 at 12 weeks (P < 0.001), and 37.4 ± 26.7 at 24 weeks (P < 0.001). This pain reduction was associated with a significant improvement in physical function (WOMAC-C) at all time points (P < 0.05) and stiffness (WOMAC-B) at 12 weeks (P = 0.01). Eleven patients received a second injection, which was significantly correlated with body mass index >30 kg/m2 (P = 0.025). MRI evaluation of the overall population revealed an improvement in the severity of bone marrow lesions in seven patients. No adverse events were observed. Conclusions AMUC particulate injection relieved pain and improved physical function in patients with symptomatic knee OA.

1655: Long-Term Functional Outcome in Orthotopic Bladder Replacement in Women: A Single Center Study

2007 ◽  
Vol 177 (4S) ◽  
pp. 549-549
Author(s):  
Hannes Steiner ◽  
Thomas Akkad ◽  
Christian Gozzi ◽  
Brigitte Springer-Stoehr ◽  
Georg Bartsch
Keyword(s):  
Functional Outcome ◽  
Single Center ◽  
Bladder Replacement ◽  
Single Center Study ◽  
Center Study
Sign in / Sign up

Export Citation Format

Share Document